These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 4203573

  • 1. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
    Aronow WS, Vangrow JS, Nelson WH, Pagano J, Papageorge's NP, Khursheed M, Harding PR, Khemka M.
    Curr Ther Res Clin Exp; 1973 Dec; 15(12):902-6. PubMed ID: 4203573
    [No Abstract] [Full Text] [Related]

  • 2. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
    Wolfram G, Keller C, Kilani C, Zöllner N.
    Verh Dtsch Ges Inn Med; 1973 Dec; 79():1291-3. PubMed ID: 4597609
    [No Abstract] [Full Text] [Related]

  • 3. Long-term effect of halofenate on serum lipids.
    Aronow WS, Vangrow J, Pagano J, Khemka M, Vawter M, Papageorge's NP.
    Curr Ther Res Clin Exp; 1974 Sep; 16(9):897-903. PubMed ID: 4214664
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
    Bassett DR, Mikkelsen WM, Buckingham RB, Block WD, Sidiq M, Shakibai A, DiGaetano R, Liou LL.
    Clin Pharmacol Ther; 1977 Sep; 22(3):340-51. PubMed ID: 330079
    [No Abstract] [Full Text] [Related]

  • 7. The metabolic spectrum of halofenate.
    Ryan JR.
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA, Azarnoff DL, Huffman DH, Pentikäinen P, Hurwitz A, Shoeman DW.
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [Abstract] [Full Text] [Related]

  • 11. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J, de Neuman MP, Talmasky S, Pesce R, Valero E, Martiarena JL.
    J Cardiovasc Surg (Torino); 1973 Mar; Spec No():532-7. PubMed ID: 4377715
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Studies of the uricosuric action of the hypolipidemic drug halofenate.
    Ravenscroft PJ, Sands JM, Emmerson BT.
    Clin Pharmacol Ther; 1973 Mar; 14(4):547-51. PubMed ID: 4723262
    [No Abstract] [Full Text] [Related]

  • 16. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
    Jain AK, Ryan JR, McMahon FG.
    N Engl J Med; 1975 Dec 18; 293(25):1283-6. PubMed ID: 171574
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
    Hutchison JC, Wilkinson WH.
    Atherosclerosis; 1973 Dec 18; 18(3):353-62. PubMed ID: 4584481
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.